Dr. Reddy's Laboratories Limited
NYSE:RDYDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $12.48B
- Beta
- 0.26
- P/E (TTM)
- 24.7
- EPS (TTM)
- $51.40
- Dividend yield
- 0.63%
Volume 1.79M
Average 2.39M
RDY Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Dr. Reddy's Laboratories LimitedNYSE: RDY
Financing Cash Flow · Q2 FY2027 · quarter ended Sep 2026
Financing cash flow grows, but more slowly than its trailing trend
Q2 FY2027 financing cash flow of ₹6.32B (cash outflow) rose 18.7% year over year, behind the +123.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 11.2% from the prior quarter.
Context
- Financing cash flow amounted to 3.8% of revenue in FY2026, down 2.0 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +18.7% toward the trailing-twelve-month pace of +123.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
INR · from the cash flow
- Latest · FY2026
- 13.4B INR
- Year-over-year change
- -29.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 13.4B | -29.2% |
| FY2025 | 2025-03-31 | 18.91B | +602.6% |
| FY2024 | 2024-03-31 | (3.76B) | +86.0% |
| FY2023 | 2023-03-31 | (26.86B) | -1009.0% |
| FY2022 | 2022-03-31 | (2.42B) | — |
Financing Cash Flow vs competitors
How RDY compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +123.1% is the 2nd highest of 8, against a peer median of -50.8%.
- Financing cash flow amounts to 0.9% of revenue for RDY, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹3.08B INR | +123.1% | — | 0.9% | |
| FY2025 | £2.55B GBP | +66.2% | — | 23.2% | |
| LTM Jun 2026 | $1.91B USD | -50.8% | -30.6% | 13.0% | |
| LTM Jun 2026 | $1.1B USD | -1097.9% | +16.1% | 10.1% | |
| LTM Jun 2026 | $401M USD | -83.4% | +13.1% | 2.3% | |
| LTM Mar 2026 | $83.13M USD | +1.5% | +36.6% | 11.5% | |
| LTM Jun 2026 | $69.63M USD | +129.7% | -33.4% | 2.2% | |
| LTM Mar 2026 | $21.65M USD | -107.9% | +24.7% | 2.3% | |
| Peer median (excluding RDY) | — | -50.8% | +14.6% | 10.1% | |
Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 23.57B | 45.07B | 55.68B | 57.25B | 45.09B |
| Depreciation & Amortization | 11.82B | 12.64B | 14.84B | 17.06B | 21.68B |
| Deferred Income Tax | 8.73B | 15.3B | 16.19B | 19.54B | 0 |
| Stock-Based Compensation | 592M | 397M | 407M | 424M | 0 |
| Change in Working Capital | (13.91B) | (7.86B) | (20.18B) | (29.99B) | (12.24B) |
| Accounts Receivables | (17.01B) | (5.75B) | (8.05B) | (10.28B) | (7.07B) |
| Inventory | (5.33B) | (2.65B) | (18.45B) | (12.75B) | (9.05B) |
| Accounts Payables | 17.01B | 0 | 0 | 0 | 2.94B |
| Other Working Capital | (8.59B) | 551M | 6.32B | (6.95B) | 943.83M |
| Other Non-Cash Items | (2.69B) | (6.67B) | (21.5B) | (17.85B) | 2.12B |
| Operating Cash Flow | 28.11B | 58.88B | 45.43B | 46.43B | 56.65B |
| Capital Expenditures | (19.05B) | (18.87B) | (27.44B) | (34.4B) | (24.54B) |
| Acquisitions (Net) | (326M) | 0 | (12M) | (53.41B) | (2.99B) |
| Purchases of Investments | (88.97B) | (136.17B) | (145.49B) | (254.46B) | (49.21B) |
| Sales of Investments | 77.77B | 112.81B | 129.78B | 279.58B | 20.63B |
| Other Investing Activities | 4.19B | (6.68B) | (8.16B) | (2.28B) | 1.47B |
| Investing Cash Flow | (26.39B) | (41.37B) | (40.28B) | (58.08B) | (70.53B) |
| Debt Repayment | 2.74B | (20.4B) | 4.35B | 23.2B | 21.31B |
| Common Stock Issued | 334M | 368M | 805M | 193M | 417.73M |
| Common Stock Repurchased | 0 | 0 | 0 | (1.39B) | 0 |
| Dividends Paid | (4.15B) | (4.98B) | (6.65B) | (6.66B) | (7.01B) |
| Other Financing Activities | (1.35B) | (1.85B) | (2.27B) | 3.57B | (1.33B) |
| Financing Cash Flow | (2.42B) | (26.86B) | (3.76B) | 18.91B | 13.4B |
| Effect of Forex Changes | 733M | 286M | (59M) | 224M | (383.41M) |
| Net Change in Cash | 32M | (9.07B) | 1.33B | 7.49B | (875.84M) |
| Free Cash Flow | 9.06B | 40.01B | 18B | 12.03B | 32.1B |
Dr. Reddy's Laboratories Limited
NYSE:RDY
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.